This ExpertREACT article was originally published on 28 July 2008. Deal terms and pipeline positions described reflect the state of knowledge at that date.
Sanofi acquires Acambis: finalising the partnership
On 25 July 2008, Sanofi Pasteur communicated its intention to acquire UK/US-based Acambis plc - a move widely anticipated by industry observers. Sanofi's offer of a 65.2% premium on Acambis' share price valued the company at approximately £276m. The acquisition gave Sanofi full rights to the ChimeriVax technology platform and its most commercially advanced programmes: ACAM-C-DIFF (Clostridium difficile vaccine) and ACAM-FLU-A (influenza vaccine), in addition to ChimeriVax-West Nile, ChimeriVax-JE and ACAM2000 (smallpox). Sanofi had already signed prior deals with Acambis in 2006-07 based on the ChimeriVax series for Japanese encephalitis and dengue, with many observing that those early agreements had paved the way for full acquisition.
Acambis, originally founded in 1993 as Peptide Therapeutics and transformed into a vaccine company through its 1999 acquisition of US-based Oravax, had built its early identity around the biodefence segment - particularly the ACAM2000 smallpox vaccine under President Bush's Project Bioshield initiative. While biodefence revenues had been significant, by 2008 Acambis' pipeline had diversified into infectious disease vaccines with commercial potential beyond government procurement. With fewer than 200 employees and revenues below £50m, Acambis was one of the last remaining attractive vaccine company targets for a large player seeking pipeline expansion rather than market entry.
Consolidation wave continues
VacZine Analytics placed the Sanofi-Acambis deal in the context of a continuing wave of vaccine company consolidation that had accelerated since Novartis' acquisition of Chiron in April 2006. Pfizer (Powdermed/Coley/AstraZeneca's biologic acquisitions), AstraZeneca/Medimmune and smaller deals such as Intercell's acquisition of Iomai Corporation all reflected the same underlying dynamic: established players acquiring technology platforms and pipeline assets to remain competitive as organic R&D alone became insufficient to sustain pipeline breadth. With the major attractive independent vaccine companies now largely absorbed, the consolidation wave was expected to shift towards earlier-stage biotechnology partnerships and licensing agreements.